Entera Financial Statements From 2010 to 2022

ENTX
 Stock
  

USD 1.88  0.10  5.62%   

Entera Bio financial statements provide useful quarterly and yearly information to potential Entera Bio investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Entera Bio financial statements helps investors assess Entera Bio's valuation, profitability, and current liquidity needs.
We have found seventy-eight available fundamental signals for Entera Bio, which can be analyzed and compared to other ratios and to its rivals. Make sure you verify all of Entera Bio prevailing market performance against the performance between 2010 and 2022 to make sure the company can sustain itself down the road.
Entera Bio Average Equity is fairly stable at the moment as compared to the past year. Entera Bio reported Average Equity of 20.37 Million in 2021. Working Capital is likely to rise to about 23.9 M in 2022, whereas Average Assets are likely to drop slightly above 21.7 M in 2022.
  
Check Entera Bio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Entera main balance sheet or income statement drivers, such as Cost of Revenue of 366.7 K, Gross Profit of 187.3 K or Operating Expenses of 12.6 M, as well as many exotic indicators such as Asset Turnover of 0.0235, Book Value per Share of 0.93 or Current Ratio of 6.82. Entera financial statements analysis is a perfect complement when working with Entera Bio Valuation or Volatility modules. It can also supplement Entera Bio's financial leverage analysis and stock options assessment as well as various Entera Bio Technical models . Continue to the analysis of Entera Bio Correlation against competitors.

Entera Bio Revenues

542,526

Entera Bio Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets21.9 M26 M11.1 M
Increasing
Slightly volatile
Cash and Equivalents20.1 M24.9 MM
Increasing
Slightly volatile
Investments3.6 M3.6 MM
Decreasing
Slightly volatile
Investments Current3.6 M3.6 MM
Decreasing
Slightly volatile
Deferred Revenue15.4 K15 K190.8 K
Decreasing
Slightly volatile
Property Plant and Equipment Net406 K395 K281 K
Increasing
Slightly volatile
Tax Assets194.2 K195.3 K213.6 K
Decreasing
Slightly volatile
Trade and Non Trade Receivables248 K183 K576.1 K
Decreasing
Slightly volatile
Trade and Non Trade Payables212.7 K166 K178.2 K
Increasing
Slightly volatile
Goodwill and Intangible Assets556.5 K544.5 K630.3 K
Decreasing
Slightly volatile
Total Liabilities3.5 M3.4 M21.7 M
Decreasing
Slightly volatile
Shareholders Equity24.3 M22.6 M(10.1 M)
Increasing
Slightly volatile
Accumulated Other Comprehensive Income36.7 K36.9 K40.4 K
Decreasing
Slightly volatile
Current Assets21.1 M25.3 M10.3 M
Increasing
Slightly volatile
Assets Non Current692.1 K658 K825.9 K
Decreasing
Slightly volatile
Current Liabilities3.4 M3.2 M7.1 M
Decreasing
Slightly volatile
Liabilities Non Current267.9 K261 K14.7 M
Decreasing
Slightly volatile
Total Debt309.9 K302 K8.4 M
Decreasing
Slightly volatile
Debt Current183.7 K179 K5.4 M
Decreasing
Slightly volatile
Debt Non Current126.2 K123 KM
Decreasing
Slightly volatile
Shareholders Equity USD24.3 M22.6 M(10.1 M)
Increasing
Slightly volatile
Cash and Equivalents USD20.1 M24.9 MM
Increasing
Slightly volatile
Total Debt USD309.9 K302 K8.4 M
Decreasing
Slightly volatile

Entera Bio Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Revenues542.5 K571 K478 K
Decreasing
Stable
Cost of Revenue366.7 K373 K241.5 K
Increasing
Slightly volatile
Selling General and Administrative Expense5.8 M5.7 M3.9 M
Increasing
Slightly volatile
Research and Development Expense6.9 M6.8 M4.4 M
Increasing
Slightly volatile
Operating Expenses12.6 M12.4 M8.3 M
Increasing
Slightly volatile
Income Tax Expense(60.6 K)(59 K)7.7 K
Decreasing
Slightly volatile
Weighted Average Shares20.9 M26.1 M9.3 M
Increasing
Slightly volatile
Weighted Average Shares Diluted21.1 M26.1 M10.6 M
Increasing
Slightly volatile
Revenues USD542.5 K571 K478 K
Decreasing
Stable
Gross Profit187.3 K198 K382.8 K
Decreasing
Slightly volatile

Entera Bio Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Net Cash Flow Investment Acquisitions and DisposalsM4.6 M(1.4 M)
Increasing
Slightly volatile
Net Cash Flow from Financing20.1 M25.4 M10.3 M
Increasing
Slightly volatile
Issuance Repayment of Debt Securities (105.3 K)(102.6 K)3.8 M
Decreasing
Slightly volatile
Issuance Purchase of Equity Shares20.9 M25.4 M11.5 M
Increasing
Slightly volatile
Net Cash Flow from Investing(18.3 K)(17 K)(540 K)
Increasing
Slightly volatile
Net Cash Flow or Change in Cash and Cash Equivalents17.6 M16.3 M4.5 M
Increasing
Slightly volatile
Share Based Compensation1.8 M1.9 M1.7 M
Increasing
Very volatile
Depreciation Amortization and Accretion74.8 K53 K59.3 K
Increasing
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Earnings per Basic Share(0.48)(0.47)0.3804
Decreasing
Stable
Earnings per Diluted Share(0.48)(0.47)0.6558
Decreasing
Slightly volatile
Earnings per Basic Share USD(0.48)(0.47)0.3804
Decreasing
Stable
Return on Average Equity(0.65)(0.598)(0.0029)
Decreasing
Slightly volatile
Return on Invested Capital5.53.6411.3619
Increasing
Slightly volatile
Gross Margin0.360.3470.7686
Decreasing
Slightly volatile
Asset Turnover0.02350.0220.0339
Decreasing
Slightly volatile
Price to Earnings Ratio(6.15)(5.989)0.7516
Decreasing
Slightly volatile
Sales per Share0.02460.0220.0502
Decreasing
Slightly volatile
Price to Sales Ratio11712965.1952
Increasing
Slightly volatile
Price to Book Value3.613.5913.2964
Decreasing
Stable
Debt to Equity Ratio0.160.152(0.6794)
Increasing
Slightly volatile
Current Ratio6.828.0132.8374
Increasing
Slightly volatile
Book Value per Share0.930.863(3.2368)
Increasing
Slightly volatile
Tangible Assets Book Value per Share1.120.9941.3222
Decreasing
Very volatile

Entera Bio Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Capitalization66 M81 M38.8 M
Increasing
Slightly volatile
Enterprise Value45.7 M54 M32.5 M
Increasing
Stable
Invested Capital(1.8 M)(1.8 M)2.9 M
Decreasing
Slightly volatile
Average Equity22 M20.4 M(13.9 M)
Increasing
Slightly volatile
Average Assets21.7 M25.6 M12.4 M
Increasing
Slightly volatile
Invested Capital Average(3.5 M)(3.4 M)2.1 M
Decreasing
Slightly volatile
Tangible Asset Value21.7 M26 M10.6 M
Increasing
Slightly volatile
Working Capital23.9 M22.2 M3.7 M
Increasing
Slightly volatile

Entera Fundamental Market Drivers

Short Percent Of Float0.32%
Forward Price Earnings-2.64
Shares Short Prior Month126.66k
Average Daily Volume Last 10 Day32.05k
Average Daily Volume In Three Month34.53k
Date Short Interest15th of July 2022
Fifty Day Average1.7251
Two Hundred Day Average2.5388

Entera Upcoming Events

Upcoming Quarterly Report17th of March 2022
Next Financial Report19th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End17th of March 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

About Entera Bio Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Entera Bio income statement, its balance sheet, and the statement of cash flows. Entera Bio investors use historical funamental indicators, such as Entera Bio's revenue or net income, to determine how well the company is positioned to perform in the future. Although Entera Bio investors may use each financial statement separately, they are all related. The changes in Entera Bio's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Entera Bio's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Entera Bio Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Entera Bio. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Deferred Revenue15 K15.4 K
Cost of Revenue373 K366.7 K
Revenues571 K542.5 K
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel. Entera Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 21 people.

Entera Bio Investors Sentiment

The influence of Entera Bio's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Entera. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Entera Bio Implied Volatility

    
  23.02  
Entera Bio's implied volatility exposes the market's sentiment of Entera Bio stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Entera Bio's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Entera Bio stock will not fluctuate a lot when Entera Bio's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Entera Bio in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Entera Bio's short interest history, or implied volatility extrapolated from Entera Bio options trading.

Pair Trading with Entera Bio

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Entera Bio position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Entera Bio will appreciate offsetting losses from the drop in the long position's value.

Moving together with Entera Bio

0.68BBIBrickell Biotech Earnings Call  TomorrowPairCorr

Moving against Entera Bio

0.79CVMCel-Sci Corp Fiscal Year End 28th of December 2022 PairCorr
0.69BCABBioatla TrendingPairCorr
0.65BLUEBluebird Bio Normal TradingPairCorr
0.57MEIPMei Pharma Fiscal Year End 1st of September 2022 PairCorr
The ability to find closely correlated positions to Entera Bio could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Entera Bio when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Entera Bio - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Entera Bio to buy it.
The correlation of Entera Bio is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Entera Bio moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Entera Bio moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Entera Bio can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to the analysis of Entera Bio Correlation against competitors. Note that the Entera Bio information on this page should be used as a complementary analysis to other Entera Bio's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.

Complementary Tools for Entera Stock analysis

When running Entera Bio price analysis, check to measure Entera Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Entera Bio is operating at the current time. Most of Entera Bio's value examination focuses on studying past and present price action to predict the probability of Entera Bio's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Entera Bio's price. Additionally, you may evaluate how the addition of Entera Bio to your portfolios can decrease your overall portfolio volatility.
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Go
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
Is Entera Bio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Entera Bio. If investors know Entera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Entera Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
52.4 M
Quarterly Revenue Growth YOY
-0.57
Return On Assets
-0.42
Return On Equity
-1.0
The market value of Entera Bio is measured differently than its book value, which is the value of Entera that is recorded on the company's balance sheet. Investors also form their own opinion of Entera Bio's value that differs from its market value or its book value, called intrinsic value, which is Entera Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Entera Bio's market value can be influenced by many factors that don't directly affect Entera Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Entera Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine Entera Bio value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Entera Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.